News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference CULVER CITY, Calif.--(BUSINESS WIRE)--May 24, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder and Executive Chairman Dr. Patrick Soon-Shiong will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021. Dr. Soon-Shiong will present updates on ImmunityBio’s infectious disease and oncology programs. Management will be available during the conference for virtual one-on-one meetings. Presentation Details: Date: Friday, June 4 Time: 11:30 a.m. EDT https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-present-jefferies-2021-virtual-healthcare-conference?field_nir_news_date_value[min]=

ImmunityBio shot mulled as booster in SA Covid study ‘It could be the universal boost that we are looking for,’ Glenda Gray. ImmunityBio Inc.’s hAd5 T-cell Covid-19 vaccine candidate is being considered as a booster shot in a study of almost 500 000 South African health workers who have received Johnson & Johnson’s inoculation. The health workers, the first people outside of much smaller studies to be vaccinated in South Africa, will need a booster, said Glenda Gray, the co-lead of the South African studies, said in an interview Wednesday. ENU      Fast News    ImmunityBio shot mulled as booster in SA Covid study ‘It could be the universal boost that we are looking for,’ Glenda Gray. By Antony Sguazzin, Bloomberg 20 May 2021  09:27   Image: Eric Thayer/Bloomberg ImmunityBio Inc.’s hAd5 T-cell Covid-19 vaccine candidate is being considered as a booster shot in a study of almost 500 000 South African health workers who have received Johnson & Johnson’s inoculation. The health workers, the first people outside of much smaller studies to be vaccinated in South Africa, will need a booster, said Glenda Gray, the co-lead of the South African studies, said in an interview Wednesday.  INSIDERGOLD Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. SIGN UP Click here for more information. “It could be the universal boost that we are looking for,” she said. “Hopefully we will start in a couple of weeks.” The hAd5 T-cell kills infected cells and in addition to the spike proteins found on the coronavirus the shot targets the nucleocapsid protein, which is less prone to mutations. That could make it more effective against strains such as the one first found in South Africa in late 2020, ImmunityBio said in a statement earlier this year. ImmunityBio’s vaccine is in phase one trials in Cape Town, and the company has signed an agreement with South Africa’s BioVac Institute to produce the inoculation in the country should it win approval. A broader rollout of Covid-19 vaccines began in South Africa this week. https://www.moneyweb.co.za/news/south-africa/immunitybio-shot-mulled-as-booster-in-sa-covid-study/

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021 Chemotherapy free regimen (with NK and T cell activation via Anktiva) in patients across multiple tumor types who failed checkpoint inhibitor therapy 140 patients accrued to date in this basket trial of checkpoint failures in lung cancer, melanoma, urothelial, head & neck, gastric and cervical cancer Out of 140 patients, 121 patients evaluable to date with 68% (82 out of 121) demonstrating durable disease control following Anktiva (IL-15 superagonist) plus checkpoint therapy after checkpoint failure Adverse events (AE) rates (12% grade 3 or above) of the chemo-free combination were better than historical standard of care alternative of combination chemotherapy Promising data forms the basis for the actively recruiting randomized Phase 3 clinical trials of Anktiva combination therapy in lung cancer patients (NCT03520686) https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-present-preliminary-phase-2-data-68-durable-disease?field_nir_news_date_value[min]=

QUILT 3.076 Study Details Cryopreserved m-ceNK cells in combination with Anktiva (N-803) will be tested in this phase 1 study designed to evaluate safety in subjects with locally advanced or metastatic solid tumors. The study will compare the quantity and quality of the m-ceNK cells collected and manufactured from newly diagnosed patients who have not received prior treatment to the m-ceNK cells collected and manufactured from patients who have received at least two prior treatments for their cancer. The study consists of two cohorts and there will be 10 participants in each cohort. Cohort 1 includes participants with newly diagnosed high-risk solid tumors who have not received prior treatment; and cohort 2 includes participants with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. Participants will be enrolled in the two cohorts simultaneously. Participants in cohort 1 will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study. Participants in cohort 2 will undergo an apheresis collection of lymphocytes (part A) prior to receiving approximately four weeks of disease-specific therapy per their Oncologists’ recommendations. Solid tumors represent approximately 90% of adult cancers and 40% of all cancers in children, according to data collected from the American Cancer Society. Tumors can develop in many parts of the human body including the breast, lung, prostate, colon, skin, bladder and kidney. https://ir.immunitybio.com/news-releases/news-release-details/fda-authorizes-immunitybio-conduct-trial-its-first-human?field_nir_news_date_value[min]=

About Memory Cytokine-Enhanced NK Cells (m-ceNK): In an initial, proof-of-concept clinical study, memory-like NK cells with freshly isolated cytokine-stimulated NK cells demonstrated encouraging results in patients with liquid tumors.1. ImmunityBio has successfully enriched and expanded donor natural killer cells obtained from peripheral blood of donors using a technique called apheresis, to generate a unique NK cell phenotype which exhibits both high cytotoxicity and interferon-g production together with a memory–like effect. These m-ceNK cells, or memory-cytokine enriched NK cells, have been designed for autologous cell therapy, but have also been generated as an allogeneic product from cord blood. m-ceNK provides a unique opportunity in clinics due to its ease of use and potential suitability for use in the ambulatory setting. NK cells from aphaeretic blood from 20 subjects, 15 healthy and 5 cancer patient donors, were successfully used to generate m-ceNK cells in an Independent Review Board-approved volunteer study. Mononuclear cells obtained from the apheresis procedure were stimulated in the presence of ImmunityBio’s proprietary cytokine, N-803, for enrichment of primary natural killer cells. A 2 to 3 log-fold expansion of activated NK cells was achieved by the third week of the protocol. These NK Cells are then briefly exposed to a proprietary cytokine cocktail to impart the critical memory-like phenotype, characterized by higher effector responses after a resting period—a key feature of ImmunityBio’s m-ceNK cells. The m-ceNK product is characterized as CD56+ cells that are armed with NK cell activating surface receptors required for proliferation, homing and tumor recognition and binding. Both the healthy- and cancer patient-derived m-ceNK cells killed NK-resistant tumor cells with equal potency when tested against tumor cells of different origins, including breast, Merkel, ovarian, adenocarcinoma, and lymphoma. ImmunityBio has also developed a novel method of production, which yields multiple clinical-dose forms from a single apheresis product using the company’s proprietary NANT 001 Bioreactor (GMP-in-a-Box), thereby alleviating pressures on supply of starting material. A tailored cryopreservation protocol for maximum shelf-life and potency upon recovery was also established, a necessary precedent for any off-the-shelf product. ImmunityBio is leveraging the unique properties of m-ceNK—including potent cytotoxicity, increased IFN-gamma production, proliferative capacity, activation surface markers and memory response—to establish a propriety autologous product.

CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2021-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has received FDA authorization to conduct a Phase 1 study to evaluate the safety and preliminary efficacy of its m-ceNK™ platform combined with its IL-15 superagonist Anktiva (N-803) in subjects with locally advanced or metastatic solid tumors. These NK cells retrieved from the patient and enriched with cytokines have the ability to recognize and kill cancer targets with increased production of interferon-g (IFN-γ), a cytokine demonstrating high activity. “Nearly two million Americans, including children, will be diagnosed with locally advanced or metastatic solid tumors this year alone and many of these tumor types are difficult to treat,” said Patrick Soon-Shiong, M.D., Founder and Executive Chairman of ImmunityBio. “Our m-ceNK cells, which are isolated and enriched from the patient after a simple blood draw (apheresis), are characterized by their unique cell-surface marker profile, by their highly desirable feature of immune-memory, and marked by their pronounced anti-cancer activity for weeks to months in duration. These unique properties have made these memory NK cells a research focus for more than a decade and a promising candidate in immunotherapy for solid tumors,” said Soon-Shiong. “We are excited to launch this next evolution of our NK platform. Based on the novel techniques and cytokine expansion developed at ImmunityBio, a single apheresis will enable 10 to 20 doses of m-ceNK infusions of 0.5 billion NK cells per dose. These autologous and allogeneic cryopreserved memory NK cells could synergize with our engineered off-the-shelf NK-92 cells, as well as with our IL-15 Anktiva superagonist, which stimulates both NK and T cells. We believe the combination of these tools has the potential to place ImmunityBio in a leading position to activate the patient’s immune system in the fight against cancer across both solid and liquid tumors.”

FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors The first-in-class, memory cytokine-enriched Natural Killer (m-ceNK™) cells are the patient’s own NK cells that have been enriched with cytokines, including ImmunityBio’s IL-15 superagonist Anktiva (N-803) The resulting cryopreserved m-ceNK cells have an enhanced ability to recognize and kill cancer targets with longer persistence An initial study inolving 20 subjects (15 healthy donors and five cancer patients) showed that healthy and patient-derived m-ceNK cells killed NK-resistant tumor cells with equal potency in preclinical models Over 3000 percent m-ceNK cell expansion was achieved from a single blood draw enabling the potential for 10 to 20 infusions of a billion cells per dose The Phase 1 open-label study authorized by the FDA will begin enrolling participants with metastatic solid tumors in Q2 2021

Arbeit an T-Zell-Impfstoff Corona-Supervakzin soll jahrelang schützen Die schnelle Impfstoff-Entwicklung gegen Corona ist ein Wunder der Medizin, das mRNA-Verfahren eine kleine Revolution. Doch alle verfügbaren Vakzine müssen wohl regelmäßig aufgefrischt werden - und wirken nicht immer gegen Mutationen. Ein anderes Verfahren will beide Probleme lösen - birgt aber andere Risiken. https://www.n-tv.de/22552106 Schockierender, neuer Impfstoff...😱

Dr. Patrick Soon-Shiong, the billionaire biotechnology entrepreneur who owns The Los Angeles Times, announced on Wednesday that his corporation and his philanthropic foundation would commit an initial 3 billion South African rand (about $210 million) to transfer the latest technology for producing vaccines and biological therapies to South Africa, where he was born.

A biotech billionaire pledges $210 million to transfer vaccine technology to South Africa. https://www.nytimes.com/live/2021/05/12/world/covid-vaccine-coronavirus-cases#a-biotech-billionaire-pledges-210-million-to-transfer-vaccine-technology-to-south-africa

ImmunityBio, Inc. Twitter, vor 5 Std. : "Developed nations are in advanced stages of vaccination rollouts while the majority of African countries are experiencing shortages of initial supplies. Learn more: https://bloom.bg/2R9fvtZ"

BlackRock hat am 07.05. ihre Aktienbestände in ImmunityBio aufgestockt von 3.303.410 Millionen auf 3.553.665 Millionen. https://fintel.io/sob/us/IBRX

CYTRX hat die weltweiten Rechte an Aldoxorubicin an ImmunityBio auslizensiert. CYTRX bekommt dafür Lizenzgebühren und Meilensteinzahlungen bis zu 343 Millionen Dollar. Sind aber im Gegensatz zum Umsatz, welche solche und ähnliche Krebsmedikamente generieren, Peanuts. Also hat ImmunityBio neben Anktiva N-803 und anderen Cytokin Fusionen (N-820, N-809, N-830) auch noch das Zytostatika Aldoxorubicin, welche bald Umsatz generieren könnten! Anktiva N-803 hat die Phasen l,ll und lll am 30. September 2020 im Bereich flüssige und feste Tumore bei über 600 Patienten abgeschlossen. Zudem läuft die Registrierung zu Phase ll/lll bei nicht-muskelinvasivem Blasenkrebs. Anktiva N-803 hat, wie die Tage erwähnt, bei der FDA den Breakthrough Therapy und Fast Track Status erhalten. ImmunityBio weißt zwar daraufhin, dass dies nicht zwangsläufig zu einer schnelleren Zulassung führt, aber es ist doch ein gutes Zeichen, dass ImunityBio in nicht allzu ferner Zukunft die Zulassung/Freigabe der FDA erhält und somit die Behandlung kommerzialisieren kann und Umsätze generiert!

Dr. Pat Soon-Shiong on Twitter vor 12 Std.: "Abraxane 20 years later! Next the immune system."

Durable complete response achieved in 7 of 9 (78%) CD20 sensitive patients who failed Rituxan® therapy in Phase 1 liquid tumor trial Of those patients who responded to the combination therapy of Anktiva™ plus Rituxan, 7 out of 7 (100%) achieved a complete response Chemotherapy-free regimen with minimal toxicity potentially enhances Rituxan mAb therapy with potential for broad application across liquid tumor indications Prolonged duration of disease without progression ranging from 18 to 24 months

ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients